AU2003201693A1 - Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents - Google Patents

Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents

Info

Publication number
AU2003201693A1
AU2003201693A1 AU2003201693A AU2003201693A AU2003201693A1 AU 2003201693 A1 AU2003201693 A1 AU 2003201693A1 AU 2003201693 A AU2003201693 A AU 2003201693A AU 2003201693 A AU2003201693 A AU 2003201693A AU 2003201693 A1 AU2003201693 A1 AU 2003201693A1
Authority
AU
Australia
Prior art keywords
esters
androstane
beta
alpha
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003201693A
Inventor
Keith Biggadike
Gillian Elizabeth Morton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201357A external-priority patent/GB0201357D0/en
Priority claimed from GB0224608A external-priority patent/GB0224608D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2003201693A1 publication Critical patent/AU2003201693A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
AU2003201693A 2002-01-21 2003-01-20 Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents Abandoned AU2003201693A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0201357A GB0201357D0 (en) 2002-01-21 2002-01-21 Novel compounds
GB0201357.1 2002-01-21
GB0224608.0 2002-10-23
GB0224608A GB0224608D0 (en) 2002-10-23 2002-10-23 Novel compounds
PCT/GB2003/000234 WO2003062259A2 (en) 2002-01-21 2003-01-20 Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
AU2003201693A1 true AU2003201693A1 (en) 2003-09-02

Family

ID=27614790

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003201693A Abandoned AU2003201693A1 (en) 2002-01-21 2003-01-20 Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents

Country Status (2)

Country Link
AU (1) AU2003201693A1 (en)
WO (1) WO2003062259A2 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (en) 2004-10-22 2006-04-24 Novartis Ag ORGANIC COMPOUNDS.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
RU2421464C2 (en) 2005-10-21 2011-06-20 Новартис Аг Human il-13 antibodies and their therapeutic application
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PL2013211T3 (en) 2006-04-21 2012-08-31 Novartis Ag Purine derivatives for use as adenosin a2a receptor agonists
EP2081933B1 (en) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidines as pi3k lipid kinase inhibitors
US20080176901A1 (en) 2007-01-10 2008-07-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
AU2008248598B2 (en) 2007-05-07 2011-11-17 Novartis Ag Organic compounds
CN101939054B (en) 2007-12-10 2014-10-29 诺华股份有限公司 organic compounds
EA201001848A1 (en) 2008-06-10 2011-08-30 Новартис Аг DERIVATIVES OF PIRAZINE AS EPITELIAL SODIUM CHANNEL BLOCKS
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010076553A1 (en) 2008-12-30 2010-07-08 Dr. Reddy's Laboratories Ltd Sulfonamide compounds for the treatment of respiratory disorders
EP2391366B1 (en) 2009-01-29 2012-11-28 Novartis AG Substituted benzimidazoles for the treatment of astrocytomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
MX2012002066A (en) 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof.
AU2010284972A1 (en) 2009-08-20 2012-03-08 Novartis Ag Heterocyclic oxime compounds
JP2013508414A (en) 2009-10-22 2013-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド Compositions for the treatment of cystic fibrosis and other chronic diseases
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UY33597A (en) 2010-09-09 2012-04-30 Irm Llc COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
JP2014505088A (en) 2011-02-10 2014-02-27 ノバルティス アーゲー [1,2,4] Triazolo [4,3-b] pyridazine compounds as C-MET tyrosine kinase inhibitors
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
ES2551592T3 (en) 2011-02-25 2015-11-20 Novartis Ag Pyrazolo [1,5-a] pyridines as TRK inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
ES2691650T3 (en) 2011-09-15 2018-11-28 Novartis Ag 3- (quinolin-6-yl-thio) - [1,2,4] -triazolo- [4,3-a] -pyridines 6-substituted as inhibitors of tyrosine kinase c-Met
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP5886433B2 (en) 2011-09-16 2016-03-16 ノバルティス アーゲー Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
JP6165733B2 (en) 2011-09-16 2017-07-19 ノバルティス アーゲー N-substituted heterocyclylcarboxamides
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc Combination of kinase inhibitors and uses thereof
US10155001B2 (en) 2013-06-14 2018-12-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) RAC1 inhibitors for inducing bronchodilation
TW201605450A (en) 2013-12-03 2016-02-16 諾華公司 Combination of Mdm2 inhibitor and BRAF inhibitor and their use
US10112926B2 (en) 2014-04-24 2018-10-30 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016023967A2 (en) 2014-04-24 2017-08-15 Novartis Ag pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
CN106458979B (en) 2014-04-24 2020-03-27 诺华股份有限公司 Aminopyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
EP3174869B1 (en) 2014-07-31 2020-08-19 Novartis AG Combination therapy of a met inhibitor and an egfr inhibitor
CA3139634A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
CA3146109A1 (en) 2019-08-28 2021-03-04 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (en) 2020-01-29 2021-11-01 瑞士商諾華公司 Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3828080A (en) * 1972-01-20 1974-08-06 Glaxo Lab Ltd Androstane-17beta-carboxylic acids and processes for the preparation thereof
GB1438940A (en) * 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
GB1514476A (en) * 1974-08-30 1978-06-14 Glaxo Lab Ltd Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2003062259A2 (en) 2003-07-31
WO2003062259A3 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
AU2003201693A1 (en) Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
AU2003202044A1 (en) 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
AU2002356759A1 (en) 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
AU7649701A (en) 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
AU2002228453A1 (en) Process for the preparation of esters of (meth)acrylic acid
AU2003217619A1 (en) Shelving system
AU2002311766A1 (en) Stabilized ester peroxycarboxylic acid compositions
AU2003288686A1 (en) Compositions and systems for the regulation of genes
HK1072609A1 (en) New etonogestrel esters
ZA200305173B (en) Omega-Aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells.
AU2003211453A1 (en) External compositions for the skin
AU2003222083A1 (en) Acid and ester compounds and methods of using the same
AU1530001A (en) Inhibitor compositions
AU2003235436A1 (en) Acrylic sol composition
AU2003248094A1 (en) Shelving system
AU2002243643A1 (en) Estradiol-16alpha-carboxylic acid esters as locally active estrogens
AU2003302305A1 (en) Benzoquinolizine-2-carboxylic acid-containing compositions
ZA200300929B (en) 17.Beta.-carbothioate 17.Alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents.
AU2002249486A1 (en) Macromolecular compounds as potential anti-inflammatory agents
AU2003282510A8 (en) Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
ZA200409498B (en) Use of new etonogestrel esters
AU2003274410A1 (en) Pharmaceutical compositions of ganciclovir
AU7608100A (en) 1-cyclohexene-1-carboxylic acid and 1-cyclohexene-1-carboxylates as neuraminidase inhibitors
AU2003273705A1 (en) Shelving system
AU2003238835A1 (en) HUMAN COACTIVATOR-ASSOCIATED ARGININE METHYLTRANSFERASE 1 (hCARM1)

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase